Aspirin for Primary Prevention of Cardiovascular Events in the Elderly Current Status and Future Directions

The role of aspirin in the secondary prevention of occlusive cardiovascular events has now been well established. Given this, aspirin in primary prevention has been the focus of several large trials and subsequent meta-analyses over the past 3 decades, and yet the issue remains controversial. Recent...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs & aging Jg. 29; H. 4; S. 251 - 258
Hauptverfasser:	Ward, Stephanie A., Demos, Lisa, Workman, Barbara, McNeil, John J.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Cham Springer International Publishing 01.04.2012 Adis International
Schlagworte:	Aged Aspirin - pharmacology Biological and medical sciences Cardiovascular Diseases - prevention & control Current Opinion Geriatrics/Gerontology Humans Internal Medicine Medical sciences Medicine Medicine & Public Health Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Practice Guidelines as Topic Randomized Controlled Trials as Topic Prasugrel Aspirin Primary Prevention Ischaemic Stroke Ticagrelor Human Prostaglandin-endoperoxide synthase Enzyme Enzyme inhibitor Cardiovascular disease Acetylsalicylic acid Review Antiplatelet agent Non steroidal antiinflammatory agent Prevention Analgesic Primary Antipyretic Oxidoreductases Salicylates Elderly
ISSN:	1170-229X, 1179-1969, 1179-1969
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	The role of aspirin in the secondary prevention of occlusive cardiovascular events has now been well established. Given this, aspirin in primary prevention has been the focus of several large trials and subsequent meta-analyses over the past 3 decades, and yet the issue remains controversial. Recent studies in populations with high baseline risk — such as diabetics and those with asymptomatic peripheral arterial disease — have not found the expected benefits of aspirin on cardiovascular endpoints, which contrasts with earlier studies that reported a reduced relative risk for outcomes such as myocardial infarction and ischaemic stroke, but not for mortality. Furthermore, in healthy populations, the absolute risk reduction conferred by aspirin is small and needs to be balanced against the risk of a major haemorrhage. Older adults have a higher risk for cardiovascular events and therefore might represent the group in which aspirin for primary prevention could deliver the greatest absolute benefit, yet at the same time, the elderly bear an increased vulnerability to major haemorrhage, including haemorrhagic stroke. It is also not known whether older adults experience the same risk reduction from aspirin as middle-aged individuals. The current evidence base does not sufficiently clarify whether aspirin for primary prevention confers a meaningful net benefit in the elderly.
AbstractList	The role of aspirin in the secondary prevention of occlusive cardiovascular events has now been well established. Given this, aspirin in primary prevention has been the focus of several large trials and subsequent meta-analyses over the past 3 decades, and yet the issue remains controversial. Recent studies in populations with high baseline risk - such as diabetics and those with asymptomatic peripheral arterial disease - have not found the expected benefits of aspirin on cardiovascular endpoints, which contrasts with earlier studies that reported a reduced relative risk for outcomes such as myocardial infarction and ischaemic stroke, but not for mortality. Furthermore, in healthy populations, the absolute risk reduction conferred by aspirin is small and needs to be balanced against the risk of a major haemorrhage. Older adults have a higher risk for cardiovascular events and therefore might represent the group in which aspirin for primary prevention could deliver the greatest absolute benefit, yet at the same time, the elderly bear an increased vulnerability to major haemorrhage, including haemorrhagic stroke. It is also not known whether older adults experience the same risk reduction from aspirin as middle-aged individuals. The current evidence base does not sufficiently clarify whether aspirin for primary prevention confers a meaningful net benefit in the elderly.The role of aspirin in the secondary prevention of occlusive cardiovascular events has now been well established. Given this, aspirin in primary prevention has been the focus of several large trials and subsequent meta-analyses over the past 3 decades, and yet the issue remains controversial. Recent studies in populations with high baseline risk - such as diabetics and those with asymptomatic peripheral arterial disease - have not found the expected benefits of aspirin on cardiovascular endpoints, which contrasts with earlier studies that reported a reduced relative risk for outcomes such as myocardial infarction and ischaemic stroke, but not for mortality. Furthermore, in healthy populations, the absolute risk reduction conferred by aspirin is small and needs to be balanced against the risk of a major haemorrhage. Older adults have a higher risk for cardiovascular events and therefore might represent the group in which aspirin for primary prevention could deliver the greatest absolute benefit, yet at the same time, the elderly bear an increased vulnerability to major haemorrhage, including haemorrhagic stroke. It is also not known whether older adults experience the same risk reduction from aspirin as middle-aged individuals. The current evidence base does not sufficiently clarify whether aspirin for primary prevention confers a meaningful net benefit in the elderly. The role of aspirin in the secondary prevention of occlusive cardiovascular events has now been well established. Given this, aspirin in primary prevention has been the focus of several large trials and subsequent meta-analyses over the past 3 decades, and yet the issue remains controversial. Recent studies in populations with high baseline risk — such as diabetics and those with asymptomatic peripheral arterial disease — have not found the expected benefits of aspirin on cardiovascular endpoints, which contrasts with earlier studies that reported a reduced relative risk for outcomes such as myocardial infarction and ischaemic stroke, but not for mortality. Furthermore, in healthy populations, the absolute risk reduction conferred by aspirin is small and needs to be balanced against the risk of a major haemorrhage. Older adults have a higher risk for cardiovascular events and therefore might represent the group in which aspirin for primary prevention could deliver the greatest absolute benefit, yet at the same time, the elderly bear an increased vulnerability to major haemorrhage, including haemorrhagic stroke. It is also not known whether older adults experience the same risk reduction from aspirin as middle-aged individuals. The current evidence base does not sufficiently clarify whether aspirin for primary prevention confers a meaningful net benefit in the elderly.
Author	Ward, Stephanie A. Demos, Lisa Workman, Barbara McNeil, John J.
Author_xml	– sequence: 1 givenname: Stephanie A. surname: Ward fullname: Ward, Stephanie A. email: Stephanie.ward@monash.edu organization: The Kingston Centre, Monash Ageing Research Centre (MONARC), Department of Epidemiology and Preventive Medicine, Monash University, Western Health – sequence: 2 givenname: Lisa surname: Demos fullname: Demos, Lisa organization: Department of Epidemiology and Preventive Medicine, Monash University – sequence: 3 givenname: Barbara surname: Workman fullname: Workman, Barbara organization: The Kingston Centre, Monash Ageing Research Centre (MONARC) – sequence: 4 givenname: John J. surname: McNeil fullname: McNeil, John J. organization: Department of Epidemiology and Preventive Medicine, Monash University
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25789627$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22462627$$D View this record in MEDLINE/PubMed
BookMark	eNqNkUlLBDEQhYMojttfkL6Ip9ZsveQiyDAuMKAHBW8hna5opCcZk27Bf2_GnlHwornUg3zvJVW1j7add4BQRvAZJWVxTkghBGY4x5szqi20R0glciJKsf2lcU6peJqg_RhfE1BSSnbRhFJe0pJWe-jqMi5tsC4zPmT3wS5U-EgV3sH11rvMm2yqQmv9u4p66FTIZqurmCVL_wLZrGshdB-HaMeoLsLRuh6gx6vZw_Qmn99d304v57lmgvd5m75guGkZV5VhpgVe1IUuMRcUN7qBFhqsgSouaq4L0fASoK4YoazFWmHFDtDpmLsM_m2A2MuFjRq6TjnwQ5SiZDXDuKaJPF6TQ7OAVi7H3uSm9QScrIHUmepMUE7b-MMVVS1G7mLkdPAxBjBS216thtMHZTtJsFztRG52Ir93MqoUUP8K2LzxD6sYrTFZ3DME-eqH4NKE__Z-AtnRnoE
CitedBy_id	crossref_primary_10_1002_j_2055_2335_2013_tb00220_x crossref_primary_10_1016_j_rccar_2019_02_008 crossref_primary_10_1007_s11888_012_0151_4 crossref_primary_10_1038_s41569_019_0209_y crossref_primary_10_1016_j_jcgg_2016_03_006 crossref_primary_10_1111_bcp_13355 crossref_primary_10_1002_msj_21340
Cites_doi	10.1161/01.CIR.101.10.1206 10.1097/MAJ.0b013e3181f1fba8 10.1038/clpt.1993.115 10.1136/bmj.38456.676806.8F 10.3109/07853890.2011.582137 10.1159/000054756 10.1016/j.pharmthera.2011.01.011 10.1001/jama.295.3.306 10.1016/j.ahj.2011.04.006 10.1161/01.CIR.0000020190.45892.75 10.1089/152460900318911 10.1161/STROKEAHA.109.576975 10.1093/eurheartj/ehm248 10.1136/bmj.296.6618.313 10.1136/bmj.324.7329.71 10.1001/archinternmed.2011.628 10.3109/08037059409102281 10.1016/j.clineuro.2007.09.005 10.1056/NEJMoa050613 10.1161/01.STR.29.5.887 10.1001/jama.2010.221 10.2165/00002512-200320130-00004 10.1001/archneur.57.3.326 10.1016/j.thromres.2011.08.012 10.1001/jama.2008.623 10.1211/jpp.61.11.0010 10.2165/00002512-200522100-00005 10.1016/S0140-6736(98)04311-6 10.2217/ahe.11.11 10.1016/S0140-6736(09)60503-1 10.1016/S0140-6736(00)03539-X 10.1016/j.amjcard.2006.04.012 10.2165/00002512-200320120-00004 10.1038/nrendo.2010.169 10.1136/bmj.a1840 10.1016/j.bpa.2011.05.002 10.2174/157016111797484189 10.1016/j.amjcard.2011.02.325 10.7326/0003-4819-150-6-200903170-00008 10.2337/dc10-0555 10.1016/j.diabres.2009.09.029 10.1056/NEJM198907203210301 10.5694/j.1326-5377.2008.tb01932.x
ContentType	Journal Article
Copyright	Adis Data Information BV 2012 2015 INIST-CNRS
Copyright_xml	– notice: Adis Data Information BV 2012 – notice: 2015 INIST-CNRS
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8
DOI	10.2165/11599030-000000000-00000
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1179-1969
EndPage	258
ExternalDocumentID	22462627 25789627 10_2165_11599030_000000000_00000
Genre	Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GroupedDBID	--- -EM -~X .GJ 04C 0R~ 199 29G 2JY 34G 36B 39C 3V. 4.4 406 53G 5GY 5RE 6I2 6PF 7RV 7X7 88E 8FI 8FJ 8R4 8R5 95. AAAUJ AACDK AADNT AAIAL AAIKX AAJKR AAKAS AANZL AARHV AASML AATNV AAWTL AAYQN AAYTO AAYZH ABAKF ABDBF ABDZT ABFTV ABIPD ABIVO ABJNI ABJOX ABKCH ABKMS ABKTR ABLLE ABPLI ABTKH ABTMW ABUWG ABWHX ABXPI ACAOD ACCOQ ACCUX ACDTI ACGFS ACMJI ACMLO ACOKC ACPIV ACREN ACZOJ ADBBV ADFRT ADFZG ADHHG ADJJI ADOJX ADQRH ADRFC ADURQ ADYOE ADZCM ADZKW AEBTG AEFQL AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AEVLU AEXYK AEYRQ AFBBN AFKRA AFZKB AGAYW AGDGC AGQEE AGQMX AGRTI AHIZS AHMBA AHSBF AIAKS AIGIU AILAN AJRNO ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMXSW AMYLF ASPBG AVWKF AWSVR AXYYD AZFZN AZQEC A~4 BENPR BGNMA BKEYQ BMSDO BPHCQ BVXVI BYPQX CAG CCPQU COF CS3 DCUDU DNIVK DPUIP DWQXO EAP EBLON EBS ECF ECT ECV EIHBH EJD EMB EMK EMOBN ENC ESX EX3 F5P F8P FERAY FIGPU FLLZZ FNLPD FSGXE FYUFA GNUQQ HMCUK HZ~ IAO IEA IHR IMOTQ INH INR ITC IWAJR J-C JZLTJ LGEZI LLZTM LOTEE M1P M2M M4Y NADUK NAPCQ NQJWS NU0 NXXTH O9- OAC OPC OVD P2P PCD PQQKQ PROAC PSQYO PSYQQ Q2X ROL RSV RZALA SISQX SJN SJYHP SNPRN SNX SOHCF SOJ SPKJE SRMVM SSLCW SV3 TEORI TSG U5U U9L UG4 UKHRP UNMZH UTJUX VDBLX VFIZW W48 WAF WOW WQ9 YFH Z0Y ZMTXR ~JE AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AFOHR AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY IQODW CGR CUY CVF ECM EIF NPM 7X8
ID	FETCH-LOGICAL-c394t-d000f4fd34a7f3fde4585c604920bcbedeb0ce2a4984c59b46ee873123d0ca0a3
IEDL.DBID	RSV
ISICitedReferencesCount	7
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000303094400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1170-229X 1179-1969
IngestDate	Sun Nov 09 10:09:19 EST 2025 Mon Jul 21 05:19:22 EDT 2025 Mon Jul 21 09:13:56 EDT 2025 Sat Nov 29 06:30:43 EST 2025 Tue Nov 18 21:21:39 EST 2025 Fri Feb 21 02:29:09 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	Prasugrel Aspirin Primary Prevention Ischaemic Stroke Ticagrelor Human Prostaglandin-endoperoxide synthase Enzyme Enzyme inhibitor Cardiovascular disease Acetylsalicylic acid Review Antiplatelet agent Non steroidal antiinflammatory agent Prevention Analgesic Primary Antipyretic Oxidoreductases Salicylates Elderly
Language	English
License	CC BY 4.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c394t-d000f4fd34a7f3fde4585c604920bcbedeb0ce2a4984c59b46ee873123d0ca0a3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
PMID	22462627
PQID	963830082
PQPubID	23479
PageCount	8
ParticipantIDs	proquest_miscellaneous_963830082 pubmed_primary_22462627 pascalfrancis_primary_25789627 crossref_citationtrail_10_2165_11599030_000000000_00000 crossref_primary_10_2165_11599030_000000000_00000 springer_journals_10_2165_11599030_000000000_00000
PublicationCentury	2000
PublicationDate	20120400
PublicationDateYYYYMMDD	2012-04-01
PublicationDate_xml	– month: 4 year: 2012 text: 20120400
PublicationDecade	2010
PublicationPlace	Cham
PublicationPlace_xml	– name: Cham – name: Auckland – name: New Zealand
PublicationTitle	Drugs & aging
PublicationTitleAbbrev	Drugs Aging
PublicationTitleAlternate	Drugs Aging
PublicationYear	2012
Publisher	Springer International Publishing Adis International
Publisher_xml	– name: Springer International Publishing – name: Adis International
References	Andrawes, Bussy, Belmin (CR32) 2005; 22 Di Minno, Russolillo, Camera (CR42) 2011; 9 Russolillo, Di Minno, Tufano (CR41) 2012; 129 Seok, Joo, Yoon (CR34) 2008; 110 Voko, Koudstaal, Bots (CR39) 2001; 20 Nelson, Reid, Ames (CR45) 2008; 189 Nelson, Reid, Beilin (CR6) 2003; 20 Baigent, Blackwell, Collins (CR21) 2009; 373 Pignone, Williams (CR30) 2010; 6 (CR9) 1998; 351 (CR8) 1989; 321 de Gaetano (CR12) 2001; 357 Kronmal, Hart, Manolio (CR38) 1998; 29 Awtry, Loscalzo (CR1) 2000; 101 Pignone, Alberts, Colwell (CR29) 2010; 33 Nicolucci, De Beradis, Sacco (CR27) 2007; 28 Nelson, Liew, Bertram (CR44) 2005; 330 Bartolucci, Tendera, Howard (CR22) 2011; 107 Fitzgerald, Pirmohamed (CR33) 2011; 130 Park, Park, Oh (CR36) 2011; 7 Seshasai, Wijesuriya, Sivakumaran (CR24) 2012; 172 Ogawa, Nakayama, Morimoto (CR15) 2008; 300 Peto, Gray, Collins (CR7) 1988; 296 Mahe, Leizorovicz, Caulin (CR4) 2003; 20 Minno, Guida, Camera (CR43) 2011; 43 Gao, Adhikari, Peng (CR2) 2009; 61 Belch, MacCuish, Campbell (CR16) 2008; 337 Ward, Parikh, Workman (CR35) 2011; 25 Pearson, Blair, Daniels (CR28) 2002; 106 CR46 Hansson, Zanchetti, Carruthers (CR10) 1998; 351 Rexrode, Lee, Cook (CR14) 2000; 9 Stavrakis, Stoner, Azar (CR25) 2011; 341 Hansson, Zanchetti (CR11) 1994; 3 Thoonsen, Richard, Bentham (CR40) 2010; 41 (CR31) 2011 Silagy, McNeil, Donnan (CR37) 1993; 54 Bartolucci, Howard (CR19) 2006; 98 Zhang, Sun, Zhang (CR26) 2010; 87 Ridker, Cook, Lee (CR13) 2005; 352 Fowkes, Price, Stewart (CR17) 2010; 303 (CR3) 2002; 324 (CR5) 2009; 150 Berger, Roncaglioni, Avanzini (CR20) 2006; 295 Berger, Lala, Krantz (CR23) 2011; 162 Hart, Halperin, McBride (CR18) 2000; 57 Pearson (R28-1-20120331) 2002; 106 Seshasai (R24-1-20120331) 2012 Feb 13; 172 de Gaetano (R12-1-20120331) 2001; 357 Andrawes (R32-1-20120331) 2005; 22 Pignone (R30-1-20120331) 2010; 6 Rexrode (R14-1-20120331) 2000; 9 Fitzgerald (R33-1-20120331) 2011; 130 Di Minno (R42-1-20120331) 2011; 9 Baigent (R21-1-20120331) 2009; 373 Nicolucci (R27-1-20120331) 2007; 28 Nelson (R45-1-20120331) 2008; 189 Hart (R18-1-20120331) 2000; 57 Stavrakis (R25-1-20120331) 2011; 341 Belch (R16-1-20120331) 2008; 337 Voko (R39-1-20120331) 2001; 20 (R3-1-20120331) 2002; 324 (R5-1-20120331) 2009; 150 Peto (R7-1-20120331) 1988; 296 Zhang (R26-1-20120331) 2010; 87 Ridker (R13-1-20120331) 2005; 352 Bartolucci (R19-1-20120331) 2006; 98 Nelson (R44-1-20120331) 2005; 330 Thoonsen (R40-1-20120331) 2010; 41 (R8-1-20120331) 1989; 321 Pignone (R29-1-20120331) 2010; 33 Hansson (R11-1-20120331) 1994; 3 Berger (R23-1-20120331) 2011; 162 Bartolucci (R22-1-20120331) 2011; 107 Seok (R34-1-20120331) 2008; 110 Mahe (R4-1-20120331) 2003; 20 Park (R36-1-20120331) 2011; 7 Ogawa (R15-1-20120331) 2008; 300 Kronmal (R38-1-20120331) 1998; 29 Silagy (R37-1-20120331) 1993; 54 Fowkes (R17-1-20120331) 2010; 303 Ward (R35-1-20120331) 2011 Sep; 25 Gao (R2-1-20120331) 2009; 61 Berger (R20-1-20120331) 2006; 295 Minno (R43-1-20120331) 2011; 43 Nelson (R6-1-20120331) 2003; 20 Hansson (R10-1-20120331) 1998; 351 Russolillo (R41-1-20120331) 2012 Jan; 129 Awtry (R1-1-20120331) 2000; 101 21295071 - Pharmacol Ther. 2011 May;130(2):213-25 20197530 - JAMA. 2010 Mar 3;303(9):841-8 19903376 - J Pharm Pharmacol. 2009 Nov;61(11):1505-10 7866597 - Blood Press. 1994 Sep;3(5):322-7 20930165 - Stroke. 2010 Nov;41(11):2690-2 18997198 - JAMA. 2008 Nov 12;300(18):2134-41 20508233 - Diabetes Care. 2010 Jun;33(6):1395-402 21925398 - Best Pract Res Clin Anaesthesiol. 2011 Sep;25(3):305-17 19853947 - Diabetes Res Clin Pract. 2010 Feb;87(2):211-8 18927173 - BMJ. 2008 Oct 16;337:a1840 16950176 - Am J Cardiol. 2006 Sep 15;98(6):746-50 20856266 - Nat Rev Endocrinol. 2010 Nov;6(11):619-28 21481826 - Am J Cardiol. 2011 Jun 15;107(12):1796-801 16418466 - JAMA. 2006 Jan 18;295(3):306-13 19482214 - Lancet. 2009 May 30;373(9678):1849-60 10718501 - J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):19-27 11786451 - BMJ. 2002 Jan 12;324(7329):71-86 22231610 - Arch Intern Med. 2012 Feb 13;172(3):209-16 8330469 - Clin Pharmacol Ther. 1993 Jul;54(1):84-9 16245959 - Drugs Aging. 2005;22(10):859-76 9635947 - Lancet. 1998 Jun 13;351(9118):1755-62 14565783 - Drugs Aging. 2003;20(12):897-903 21191260 - Am J Med Sci. 2011 Jan;341(1):1-9 12119259 - Circulation. 2002 Jul 16;106(3):388-91 15753114 - N Engl J Med. 2005 Mar 31;352(13):1293-304 19293072 - Ann Intern Med. 2009 Mar 17;150(6):396-404 17604291 - Eur Heart J. 2007 Aug;28(16):1925-7 9596230 - Stroke. 1998 May;29(5):887-94 11197445 - Lancet. 2001 Jan 13;357(9250):89-95 15908442 - BMJ. 2005 Jun 4;330(7503):1306 2664511 - N Engl J Med. 1989 Jul 20;321(3):198-204 11174044 - Neuroepidemiology. 2001 Feb;20(1):40-4 17964711 - Clin Neurol Neurosurg. 2008 Feb;110(2):110-6 21815879 - Ann Med. 2011 Nov;43(7):531-44 3125882 - Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):313-6 10714657 - Arch Neurol. 2000 Mar;57(3):326-32 10715270 - Circulation. 2000 Mar 14;101(10):1206-18 21742097 - Am Heart J. 2011 Jul;162(1):115-24.e2 14561103 - Drugs Aging. 2003;20(13):999-1010 18637782 - Med J Aust. 2008 Jul 21;189(2):105-9 21907395 - Thromb Res. 2012 Jan;129(1):3-8 21143164 - Curr Vasc Pharmacol. 2011 Nov;9(6):723-32
References_xml	– volume: 101 start-page: 1206 issue: 10 year: 2000 end-page: 18 ident: CR1 article-title: Aspirin publication-title: Circulation doi: 10.1161/01.CIR.101.10.1206 – volume: 341 start-page: 1 issue: 1 year: 2011 end-page: 9 ident: CR25 article-title: Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis publication-title: Am J Med Sci doi: 10.1097/MAJ.0b013e3181f1fba8 – volume: 54 start-page: 84 issue: 1 year: 1993 end-page: 9 ident: CR37 article-title: Adverse effects of low-dose aspirin in a healthy elderly population publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1993.115 – volume: 330 start-page: 1306 issue: 7503 year: 2005 ident: CR44 article-title: Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70 publication-title: BMJ doi: 10.1136/bmj.38456.676806.8F – volume: 43 start-page: 531 issue: 7 year: 2011 end-page: 44 ident: CR43 article-title: Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention publication-title: Ann Med doi: 10.3109/07853890.2011.582137 – volume: 20 start-page: 40 issue: 1 year: 2001 end-page: 4 ident: CR39 article-title: Aspirin use and risk of stroke in the elderly: the Rotterdam Study publication-title: Neuroepi-demiology doi: 10.1159/000054756 – volume: 130 start-page: 213 issue: 2 year: 2011 end-page: 25 ident: CR33 article-title: Aspirin resistance: effect of clinical, biochemical and genetic factors publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2011.01.011 – volume: 295 start-page: 306 issue: 3 year: 2006 end-page: 13 ident: CR20 article-title: Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials publication-title: JAMA doi: 10.1001/jama.295.3.306 – volume: 162 start-page: 115 issue: 1 year: 2011 end-page: 24 ident: CR23 article-title: Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials publication-title: Am Heart J doi: 10.1016/j.ahj.2011.04.006 – year: 2011 ident: CR31 publication-title: Cardiovascular disease: Australian facts 2011 – volume: 106 start-page: 388 issue: 3 year: 2002 end-page: 91 ident: CR28 article-title: AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee publication-title: Circulation doi: 10.1161/01.CIR.0000020190.45892.75 – volume: 9 start-page: 19 issue: 1 year: 2000 end-page: 27 ident: CR14 article-title: Baseline characteristics of participants in the Women’s Health Study publication-title: J Womens Health Gend Based Med doi: 10.1089/152460900318911 – volume: 41 start-page: 2690 issue: 11 year: 2010 end-page: 2 ident: CR40 article-title: Aspirin in Alzheimer’s disease: increased risk of intracerebral hemorrhage: cause for concern? publication-title: Stroke doi: 10.1161/STROKEAHA.109.576975 – volume: 28 start-page: 1925 issue: 16 year: 2007 end-page: 7 ident: CR27 article-title: AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions publication-title: Eur Heart J doi: 10.1093/eurheartj/ehm248 – volume: 296 start-page: 313 issue: 6618 year: 1988 end-page: 6 ident: CR7 article-title: Randomised trial of prophylactic daily aspirin in British male doctors publication-title: Br Med J (Clin Res Ed) doi: 10.1136/bmj.296.6618.313 – volume: 324 start-page: 71 issue: 7329 year: 2002 end-page: 86 ident: CR3 article-title: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients publication-title: BMJ doi: 10.1136/bmj.324.7329.71 – volume: 172 start-page: 209 issue: 3 year: 2012 end-page: 16 ident: CR24 article-title: Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials publication-title: Arch Intern Med doi: 10.1001/archinternmed.2011.628 – volume: 3 start-page: 322 issue: 5 year: 1994 end-page: 7 ident: CR11 article-title: The Hypertension Optimal Treatment (HOT) study: patient characteristics: randomization, risk profiles, and early blood pressure results publication-title: Blood Press doi: 10.3109/08037059409102281 – volume: 110 start-page: 110 issue: 2 year: 2008 end-page: 6 ident: CR34 article-title: Can aspirin resistance be clinically predicted in stroke patients? publication-title: Clin Neurol Neuro-surg doi: 10.1016/j.clineuro.2007.09.005 – volume: 352 start-page: 1293 issue: 13 year: 2005 end-page: 304 ident: CR13 article-title: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women publication-title: N Engl J Med doi: 10.1056/NEJMoa050613 – volume: 29 start-page: 887 issue: 5 year: 1998 end-page: 94 ident: CR38 article-title: Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group publication-title: Stroke doi: 10.1161/01.STR.29.5.887 – volume: 303 start-page: 841 issue: 9 year: 2010 end-page: 8 ident: CR17 article-title: Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.2010.221 – volume: 189 start-page: 105 issue: 2 year: 2008 end-page: 9 ident: CR45 article-title: Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study publication-title: Med J Aust – ident: CR46 – volume: 20 start-page: 999 issue: 13 year: 2003 end-page: 1010 ident: CR4 article-title: Aspirin for the prevention of cardiovascular events in the elderly publication-title: Drugs Aging doi: 10.2165/00002512-200320130-00004 – volume: 57 start-page: 326 issue: 3 year: 2000 end-page: 32 ident: CR18 article-title: Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses publication-title: Arch Neurol doi: 10.1001/archneur.57.3.326 – volume: 129 start-page: 3 issue: 1 year: 2012 end-page: 8 ident: CR41 article-title: Filling the gap between science and clinical practice: prevention of stroke recurrence publication-title: Thromb Res doi: 10.1016/j.thromres.2011.08.012 – volume: 321 issue: 3 year: 1989 ident: CR8 publication-title: N Engl J Med – volume: 300 start-page: 2134 issue: 18 year: 2008 end-page: 41 ident: CR15 article-title: Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial publication-title: JAMA doi: 10.1001/jama.2008.623 – volume: 61 start-page: 1505 issue: 11 year: 2009 end-page: 10 ident: CR2 article-title: Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome publication-title: J Pharm Pharmacol doi: 10.1211/jpp.61.11.0010 – volume: 22 start-page: 859 issue: 10 year: 2005 end-page: 76 ident: CR32 article-title: Prevention of cardiovascular events in elderly people publication-title: Drugs Aging doi: 10.2165/00002512-200522100-00005 – volume: 351 start-page: 1755 issue: 9118 year: 1998 end-page: 62 ident: CR10 article-title: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group publication-title: Lancet doi: 10.1016/S0140-6736(98)04311-6 – volume: 7 start-page: 311 issue: 2 year: 2011 end-page: 20 ident: CR36 article-title: Antiplatelet therapy in elderly patients publication-title: Aging Health doi: 10.2217/ahe.11.11 – volume: 373 start-page: 1849 issue: 9678 year: 2009 end-page: 60 ident: CR21 article-title: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials publication-title: Lancet doi: 10.1016/S0140-6736(09)60503-1 – volume: 357 start-page: 89 issue: 9250 year: 2001 end-page: 95 ident: CR12 article-title: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project publication-title: Lancet doi: 10.1016/S0140-6736(00)03539-X – volume: 98 start-page: 746 issue: 6 year: 2006 end-page: 50 ident: CR19 article-title: Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2006.04.012 – volume: 20 start-page: 897 issue: 12 year: 2003 end-page: 903 ident: CR6 article-title: Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE) publication-title: Drugs Aging doi: 10.2165/00002512-200320120-00004 – volume: 351 issue: 9098 year: 1998 ident: CR9 publication-title: Lancet – volume: 6 start-page: 619 issue: 11 year: 2010 end-page: 28 ident: CR30 article-title: Aspirin for primary prevention of cardiovascular disease in diabetes mellitus publication-title: Nat Rev En-docrinol doi: 10.1038/nrendo.2010.169 – volume: 337 start-page: a1840 year: 2008 ident: CR16 article-title: The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease publication-title: BMJ doi: 10.1136/bmj.a1840 – volume: 25 start-page: 305 issue: 3 year: 2011 end-page: 17 ident: CR35 article-title: Health perspectives: the international epidemiology of ageing publication-title: Best Pract Res Clin Anaesthesiol doi: 10.1016/j.bpa.2011.05.002 – volume: 9 start-page: 723 issue: 6 year: 2011 end-page: 32 ident: CR42 article-title: New anti-thrombotic drugs for stroke prevention publication-title: Curr Vasc Pharmacol doi: 10.2174/157016111797484189 – volume: 107 start-page: 1796 issue: 12 year: 2011 end-page: 801 ident: CR22 article-title: Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2011.02.325 – volume: 150 start-page: 396 issue: 6 year: 2009 end-page: 404 ident: CR5 article-title: Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-6-200903170-00008 – volume: 33 start-page: 1395 issue: 6 year: 2010 end-page: 402 ident: CR29 article-title: Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation publication-title: Diabetes Care doi: 10.2337/dc10-0555 – volume: 87 start-page: 211 issue: 2 year: 2010 end-page: 8 ident: CR26 article-title: Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2009.09.029 – volume: 98 start-page: 746 issue: 6 year: 2006 ident: R19-1-20120331 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2006.04.012 – volume: 43 start-page: 531 issue: 7 year: 2011 ident: R43-1-20120331 publication-title: Ann Med doi: 10.3109/07853890.2011.582137 – volume: 22 start-page: 859 issue: 10 year: 2005 ident: R32-1-20120331 publication-title: Drugs Aging doi: 10.2165/00002512-200522100-00005 – volume: 20 start-page: 40 issue: 1 year: 2001 ident: R39-1-20120331 publication-title: Neuroepidemiology doi: 10.1159/000054756 – volume: 330 start-page: 1306 issue: 7503 year: 2005 ident: R44-1-20120331 publication-title: BMJ doi: 10.1136/bmj.38456.676806.8F – volume: 28 start-page: 1925 issue: 16 year: 2007 ident: R27-1-20120331 publication-title: Eur Heart J doi: 10.1093/eurheartj/ehm248 – volume: 6 start-page: 619 issue: 11 year: 2010 ident: R30-1-20120331 publication-title: Nat Rev Endocrinol doi: 10.1038/nrendo.2010.169 – volume: 61 start-page: 1505 issue: 11 year: 2009 ident: R2-1-20120331 publication-title: J Pharm Pharmacol doi: 10.1211/jpp.61.11.0010 – volume: 107 start-page: 1796 issue: 12 year: 2011 ident: R22-1-20120331 publication-title: Am J Cardiol doi: 10.1016/j.amjcard.2011.02.325 – volume: 337 start-page: a1840 year: 2008 ident: R16-1-20120331 publication-title: BMJ doi: 10.1136/bmj.a1840 – volume: 25 start-page: 305 issue: 3 year: 2011 Sep ident: R35-1-20120331 publication-title: Best Pract Res Clin Anaesthesiol doi: 10.1016/j.bpa.2011.05.002 – volume: 129 start-page: 3 issue: 1 year: 2012 Jan ident: R41-1-20120331 publication-title: Thromb Res doi: 10.1016/j.thromres.2011.08.012 – volume: 162 start-page: 115 issue: 1 year: 2011 ident: R23-1-20120331 publication-title: Am Heart J doi: 10.1016/j.ahj.2011.04.006 – volume: 3 start-page: 322 issue: 5 year: 1994 ident: R11-1-20120331 publication-title: Blood Press doi: 10.3109/08037059409102281 – volume: 295 start-page: 306 issue: 3 year: 2006 ident: R20-1-20120331 publication-title: JAMA doi: 10.1001/jama.295.3.306 – volume: 54 start-page: 84 issue: 1 year: 1993 ident: R37-1-20120331 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.1993.115 – volume: 324 start-page: 71 issue: 7329 year: 2002 ident: R3-1-20120331 publication-title: BMJ doi: 10.1136/bmj.324.7329.71 – volume: 150 start-page: 396 issue: 6 year: 2009 ident: R5-1-20120331 publication-title: Ann Intern Med doi: 10.7326/0003-4819-150-6-200903170-00008 – volume: 87 start-page: 211 issue: 2 year: 2010 ident: R26-1-20120331 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2009.09.029 – volume: 130 start-page: 213 issue: 2 year: 2011 ident: R33-1-20120331 publication-title: Pharmacol Ther doi: 10.1016/j.pharmthera.2011.01.011 – volume: 9 start-page: 19 issue: 1 year: 2000 ident: R14-1-20120331 publication-title: J Womens Health Gend Based Med doi: 10.1089/152460900318911 – volume: 41 start-page: 2690 issue: 11 year: 2010 ident: R40-1-20120331 publication-title: Stroke doi: 10.1161/STROKEAHA.109.576975 – volume: 321 start-page: 129 issue: 3 year: 1989 ident: R8-1-20120331 publication-title: N Engl J Med doi: 10.1056/NEJM198907203210301 – volume: 373 start-page: 1849 issue: 9678 year: 2009 ident: R21-1-20120331 publication-title: Lancet doi: 10.1016/S0140-6736(09)60503-1 – volume: 57 start-page: 326 issue: 3 year: 2000 ident: R18-1-20120331 publication-title: Arch Neurol doi: 10.1001/archneur.57.3.326 – volume: 20 start-page: 999 issue: 13 year: 2003 ident: R4-1-20120331 publication-title: Drugs Aging doi: 10.2165/00002512-200320130-00004 – volume: 303 start-page: 841 issue: 9 year: 2010 ident: R17-1-20120331 publication-title: JAMA doi: 10.1001/jama.2010.221 – volume: 33 start-page: 1395 issue: 6 year: 2010 ident: R29-1-20120331 publication-title: Diabetes Care doi: 10.2337/dc10-0555 – volume: 110 start-page: 110 issue: 2 year: 2008 ident: R34-1-20120331 publication-title: Clin Neurol Neurosurg doi: 10.1016/j.clineuro.2007.09.005 – volume: 9 start-page: 723 issue: 6 year: 2011 ident: R42-1-20120331 publication-title: Curr Vasc Pharmacol doi: 10.2174/157016111797484189 – volume: 20 start-page: 897 issue: 12 year: 2003 ident: R6-1-20120331 publication-title: Drugs Aging doi: 10.2165/00002512-200320120-00004 – volume: 351 start-page: 1755 issue: 9118 year: 1998 ident: R10-1-20120331 publication-title: Lancet doi: 10.1016/S0140-6736(98)04311-6 – volume: 29 start-page: 887 issue: 5 year: 1998 ident: R38-1-20120331 publication-title: Stroke doi: 10.1161/01.STR.29.5.887 – volume: 101 start-page: 1206 issue: 10 year: 2000 ident: R1-1-20120331 publication-title: Circulation doi: 10.1161/01.CIR.101.10.1206 – volume: 172 start-page: 209 issue: 3 year: 2012 Feb 13 ident: R24-1-20120331 publication-title: Arch Intern Med doi: 10.1001/archinternmed.2011.628 – volume: 7 start-page: 311 issue: 2 year: 2011 ident: R36-1-20120331 publication-title: Aging Health doi: 10.2217/ahe.11.11 – volume: 357 start-page: 89 issue: 9250 year: 2001 ident: R12-1-20120331 publication-title: Lancet doi: 10.1016/S0140-6736(00)03539-X – volume: 341 start-page: 1 issue: 1 year: 2011 ident: R25-1-20120331 publication-title: Am J Med Sci doi: 10.1097/MAJ.0b013e3181f1fba8 – volume: 352 start-page: 1293 issue: 13 year: 2005 ident: R13-1-20120331 publication-title: N Engl J Med doi: 10.1056/NEJMoa050613 – volume: 106 start-page: 388 issue: 3 year: 2002 ident: R28-1-20120331 publication-title: Circulation doi: 10.1161/01.CIR.0000020190.45892.75 – volume: 189 start-page: 105 issue: 2 year: 2008 ident: R45-1-20120331 publication-title: Med J Aust doi: 10.5694/j.1326-5377.2008.tb01932.x – volume: 296 start-page: 313 issue: 6618 year: 1988 ident: R7-1-20120331 publication-title: Br Med J (Clin Res Ed) doi: 10.1136/bmj.296.6618.313 – volume: 300 start-page: 2134 issue: 18 year: 2008 ident: R15-1-20120331 publication-title: JAMA doi: 10.1001/jama.2008.623 – reference: 10718501 - J Womens Health Gend Based Med. 2000 Jan-Feb;9(1):19-27 – reference: 21925398 - Best Pract Res Clin Anaesthesiol. 2011 Sep;25(3):305-17 – reference: 20930165 - Stroke. 2010 Nov;41(11):2690-2 – reference: 10714657 - Arch Neurol. 2000 Mar;57(3):326-32 – reference: 16245959 - Drugs Aging. 2005;22(10):859-76 – reference: 19482214 - Lancet. 2009 May 30;373(9678):1849-60 – reference: 18997198 - JAMA. 2008 Nov 12;300(18):2134-41 – reference: 11197445 - Lancet. 2001 Jan 13;357(9250):89-95 – reference: 9635947 - Lancet. 1998 Jun 13;351(9118):1755-62 – reference: 21742097 - Am Heart J. 2011 Jul;162(1):115-24.e2 – reference: 9596230 - Stroke. 1998 May;29(5):887-94 – reference: 15908442 - BMJ. 2005 Jun 4;330(7503):1306 – reference: 14561103 - Drugs Aging. 2003;20(13):999-1010 – reference: 16418466 - JAMA. 2006 Jan 18;295(3):306-13 – reference: 10715270 - Circulation. 2000 Mar 14;101(10):1206-18 – reference: 20197530 - JAMA. 2010 Mar 3;303(9):841-8 – reference: 21191260 - Am J Med Sci. 2011 Jan;341(1):1-9 – reference: 2664511 - N Engl J Med. 1989 Jul 20;321(3):198-204 – reference: 11174044 - Neuroepidemiology. 2001 Feb;20(1):40-4 – reference: 11786451 - BMJ. 2002 Jan 12;324(7329):71-86 – reference: 20856266 - Nat Rev Endocrinol. 2010 Nov;6(11):619-28 – reference: 20508233 - Diabetes Care. 2010 Jun;33(6):1395-402 – reference: 16950176 - Am J Cardiol. 2006 Sep 15;98(6):746-50 – reference: 17964711 - Clin Neurol Neurosurg. 2008 Feb;110(2):110-6 – reference: 21295071 - Pharmacol Ther. 2011 May;130(2):213-25 – reference: 18637782 - Med J Aust. 2008 Jul 21;189(2):105-9 – reference: 21481826 - Am J Cardiol. 2011 Jun 15;107(12):1796-801 – reference: 15753114 - N Engl J Med. 2005 Mar 31;352(13):1293-304 – reference: 19293072 - Ann Intern Med. 2009 Mar 17;150(6):396-404 – reference: 7866597 - Blood Press. 1994 Sep;3(5):322-7 – reference: 14565783 - Drugs Aging. 2003;20(12):897-903 – reference: 19903376 - J Pharm Pharmacol. 2009 Nov;61(11):1505-10 – reference: 19853947 - Diabetes Res Clin Pract. 2010 Feb;87(2):211-8 – reference: 22231610 - Arch Intern Med. 2012 Feb 13;172(3):209-16 – reference: 12119259 - Circulation. 2002 Jul 16;106(3):388-91 – reference: 21815879 - Ann Med. 2011 Nov;43(7):531-44 – reference: 8330469 - Clin Pharmacol Ther. 1993 Jul;54(1):84-9 – reference: 3125882 - Br Med J (Clin Res Ed). 1988 Jan 30;296(6618):313-6 – reference: 18927173 - BMJ. 2008 Oct 16;337:a1840 – reference: 21143164 - Curr Vasc Pharmacol. 2011 Nov;9(6):723-32 – reference: 21907395 - Thromb Res. 2012 Jan;129(1):3-8 – reference: 17604291 - Eur Heart J. 2007 Aug;28(16):1925-7
SSID	ssj0006221
Score	2.0272412
SecondaryResourceType	review_article
Snippet	The role of aspirin in the secondary prevention of occlusive cardiovascular events has now been well established. Given this, aspirin in primary prevention has...
SourceID	proquest pubmed pascalfrancis crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	251
SubjectTerms	Aged Aspirin - pharmacology Biological and medical sciences Cardiovascular Diseases - prevention & control Current Opinion Geriatrics/Gerontology Humans Internal Medicine Medical sciences Medicine Medicine & Public Health Pharmacology. Drug treatments Pharmacology/Toxicology Pharmacotherapy Practice Guidelines as Topic Randomized Controlled Trials as Topic
Subtitle	Current Status and Future Directions
Title	Aspirin for Primary Prevention of Cardiovascular Events in the Elderly
URI	https://link.springer.com/article/10.2165/11599030-000000000-00000 https://www.ncbi.nlm.nih.gov/pubmed/22462627 https://www.proquest.com/docview/963830082
Volume	29
WOSCitedRecordID	wos000303094400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1179-1969 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0006221 issn: 1170-229X databaseCode: 7X7 dateStart: 20080601 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1179-1969 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0006221 issn: 1170-229X databaseCode: 7RV dateStart: 20080601 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1179-1969 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0006221 issn: 1170-229X databaseCode: BENPR dateStart: 20080601 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Collection customDbUrl: eissn: 1179-1969 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0006221 issn: 1170-229X databaseCode: M2M dateStart: 20080601 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1179-1969 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0006221 issn: 1170-229X databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED_8QgTx-2N-jDzInjasTdqmjyobPrhR5hx7K2magCCd2Cnsv_fStBtDUdE-hJRyIb1cLr_jLncAF6kWEmE1biS0la2BwilnrVBq5XEZJJ4oVvo-6PX4aBRGZVRlXkW7Vy7JQlObYOUr37tE6IKakxb3oO1je8uwioceN5uy_zCcaWHftXeuTGEV1w1HNorn25EWjqbNF5Ejl7Qtb_EV_vzkOy2OpM72f35mB7ZKIEqureTswpLK9mC9W7ra96AR2aTW0yYZzO9o5U3SINE83fV0HzrXxln_lBGEvySyyStIlRlqnJGxJrcLQa-kbT7lBEkQfZK2qRP-PD2Ax057cHvXKqsztCQN2aSV4nQ10yllItBUp4qh5SF9tDhcJ5GJSlXimGpjLORMemHCfKV4QPGkTB0pHEEPYSUbZ-oYCE8F02GQcu0njCkvQRCnGY7nCI8KzmsQVAsTyzJ1uamg8RyjCWP4GVf8jGf8tL0aXM0oXywHfkFTX1j7GaHRbqZWUQ1IJQwxbkbjYRGZGr_lsdFm1KCqGhxZIZkTuwxtR0PsVhIRl-oi_3FKJ38hOoUNRHeuDTM6g5XJ65s6hzX5PnnKX-uwHPSHph0FRcvrsHrT7kV9fOu63Xqxmz4A3WMLBA
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED_8QgXx-2N-zDyITw67Jm3TRxkbinMMnbK3kqYJCNINO4X9916admMoKtqnQLmQXC53v-MudwBniRYSYTVeJPSVrYPCKWe1UGrlcRnEnshPuh10OrzfD7tFVmVWZruXIclcU5tk5brvXSJ0Qc1J83fQ9rOjeVhkaLdMOt_9w9NEC_uufXNlGqu4bti3WTzfzjRjmtaGIkMuadve4iv8-Sl2mpuk1sZ_NrMJ6wUQJVdWcrZgTqXbsHxXhNq34bxri1qPL0hv-kYruyDnpDstdz3egdaVCdY_pwThL-na4hWkrAw1SMlAk8ZM0itpml8ZQRJEn6Rp-oS_jHfhsdXsNa5rRXeGmqQhG9USXK5mOqFMBJrqRDH0PKSPHofrxDJWiYod022MhZxJL4yZrxQPKFrKxJHCEXQPFtJBqg6A8EQwHQYJ137MmPJiBHGa4XyO8KjgvAJBeTCRLEqXmw4aLxG6MIafUcnPaMJPO6pAfUI5tBz4BU115uwnhEa7mV5FFSClMER4GU2ERaRq8JZFRptRg6oqsG-FZErsMvQdDbFbSkRUqIvsxyUd_oXoFFaue3ftqH3TuT2CVUR6rk05OoaF0eubOoEl-T56zl6r-c35ACNACJI
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swED-ydJTBWLeua7N1mR5GnxriWrItP4YupmNtMKwbeTOyPiBQ7BAnhfz3PVl2QujYRqmfDOaMfTqdfsd9_AC-KiMkwmrcSBgruwCFU84GsTQ64DLKA1Gv9HU0mfDpNE47kLS9MHW1e5uSdD0NdkpTsRzOlakLly_CYIgwBr0orXui3eXuXsAes9RBNmr_-XvjkUPf9V9ZkhXfj6euouevb9o5pl7PRYUaM47q4k9Y9FEetT6ekoPn-rG38KYBqGTkLOoddHRxCPs3TQr-EM5SN-x6fU5ut71b1Tk5I-l2DPb6PSQjm8SfFQRhMUndUAvSTowqC1IacrlTDEvG9lFFUARRKRlb_vC79RH8Ssa3l1eDhrVhIGnMlgOFn2uYUZSJyFCjNMOIRIYYifheLnOtdO5ZFjIWcyaDOGeh1jyieIIqTwpP0A_QLcpCnwDhSjATR4qbMGdMBzmCO8PwfZ4IqOC8B1G7SJlsRppbZo27DEMbq8-s1We20ae768HFRnLuNPAfMv0dO9gIWq9nOYx6QFrDyHCT2syLKHS5qjLr5ahFWz04dgazFfYZxpRW2G-tI2vcSPXPT_r4FKEvsJ9-S7Lr75Mfn-AVAkDfVSKdQne5WOnP8FLeL2fVol9vogevthF2
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Aspirin+for+primary+prevention+of+cardiovascular+events+in+the+elderly%3A+current+status+and+future+directions&rft.jtitle=Drugs+%26+aging&rft.au=Ward%2C+Stephanie+A&rft.au=Demos%2C+Lisa&rft.au=Workman%2C+Barbara&rft.au=McNeil%2C+John+J&rft.date=2012-04-01&rft.issn=1179-1969&rft.eissn=1179-1969&rft.volume=29&rft.issue=4&rft.spage=251&rft_id=info:doi/10.2165%2F11599030-000000000-00000&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1170-229X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1170-229X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1170-229X&client=summon